The relationship between dorsolateral prefrontal N-acetylaspartate measures and striatal dopamine activity in schizophrenia

Biological Psychiatry

Volumn 45, Issue 6, 1999, Pages 660-667

  Bertolino, Alessandro ^a,b   Knable, Michael B ^a,b   Saunders, Richard C ^a,b   Callicott, Joseph H ^a,b   Kolachana, Bhaskar ^a,b   Mattay, Venkata S ^a,b   Bachevalier, Jocelyne ^b   Frank, Joseph A ^c   Egan, Michael ^a,b   Weinberger, Daniel R ^c  

^a Intramural Research Program   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c NONE

Author keywords

Dopamine; Dorsolateral prefrontal cortex; Microdialysis; N acetylaspartate; Radio receptor imaging; Striatum

Indexed keywords

DOPAMINE; N ACETYLASPARTIC ACID;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN DEVELOPMENT; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; FEMALE; HUMAN; MALE; MONKEY; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; SCHIZOPHRENIA; STRESS;

ADULT; ANIMALS; ASPARTIC ACID; CHOLINE; CHRONIC DISEASE; CORPUS STRIATUM; CREATININE; DOPAMINE; FEMALE; HUMANS; MACACA MULATTA; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NEURONS; PREFRONTAL CORTEX; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0033559047     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(98)00380-1     Document Type: Article

References (67)

1. Andreasen N.C., Flashman L., Flaum M., et al. Regional brain abnormalities in schizophrenia measured with magnetic resonance imaging. JAMA. 272:1994;1763-1769.
2. Bates T.E., Strangward M., Keelan J., Davey G.P., Munro P.M.G., Clark J.B. Inhibition of N-acetylaspartate production Implications for 1H MRS studies . Neuroreport. 7:1998;1397-1400.
3. Bertolino A., Breier A., Callicott J.H., et al. The relationship between prefrontal neuronal integrity and striatal amphetamine-induced dopamine activity in patients with schizophrenia. Neuroimage. 7:1998;S31.
4. Bertolino A., Callicott J.H., Elman I., et al. Regionally specific neuronal pathology in untreated patients with schizophrenia A proton magnetic resonance spectroscopic imaging study . Biol Psychiatry. 43:1998;641-648.
5. Bertolino A., Callicott J.H., Nawroz S., et al. Reproducibility of proton magnetic resonance spectroscopic imaging in patients with schizophrenia. Neuropsychopharmacology. 18:1998;1-9.
6. Bertolino A., Kumra S., Callicott J.H., et al. A common pattern of cortical pathology in childhood onset and adult onset schizophrenia as identified by proton magnetic resonance spectroscopic imaging. Am J Psychiatry. 155:1998;1376-1383.
7. Bertolino A., Nawroz S., Mattay V.S., et al. A specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. Am J Psychiatry. 153:1996;1554-1563.
8. Bertolino A., Saunders R.C., Mattay V.S., Bachevalier J., Frank J.A., Weinberger D.R. Proton magnetic resonance spectroscopic imaging in monkeys with mesial temporo-limbic lesions. Cereb Cortex. 7:1997;740-748.
9. Braff D.L., Heaton R., Kuck J., et al. The generalized pattern of neuropsychological deficits in outpatients with chronic schizophrenia with heterogeneous Wisconsin Card Sorting Test results. Arch Gen Psychiatry. 48:1991;891-898.
10. Breier A., Su T.P., Saunders R., et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations Evidence from a novel positron emission tomography method . PNAS. 94:1997;2569-2574.
11. Buckley P.F., Moore C., Long H., et al. 1H Magnetic resonance spectroscopy of the left temporal and frontal lobes in schizophrenia Clinical neurodevelopmental and cognitive correlates . Biol Psychiatry. 36:1994;792-800.
12. Butzlaff R.L., Hooley J.M. Expressed emotion and psychiatric relapse A meta-analysis . Arch Gen Psychiatry. 55:1998;547-552.
13. Carlsson A. The dopamine theory revisited. Hirsch S.R., Weinberger D.R. Schizophrenia. 1995;379-400 Blackwell Science LTD, Oxford.
14. Cendes F., Andermann F., Dubeau F., Matthews P.M., Arnold D.L. Normalization of neuronal metabolic dysfunction after surgery for temporal lobe epilepsy. Evidence from proton MR spectroscopic imaging. Neurology. 49:1997;1525-1533.
15. Cheng L.L., Ma M.J., Becerra L., et al. Quantitative neuropathology by high resolution magic angle spinning proton magnetic resoance spectroscopy. PNAS. 94:1997;6408-6413.
16. Claustre Y., Rivy J.P., Dennis T., Scatton B. Pharmacological studies on stress-induced increase in frontal cortical dopamine metabolism in the rat. J Pharmacol Exp Ther. 238:1986;693-700.
17. Davis K.L., Kahn R.S., Ko G., Davidson M. Dopamine in schizophrenia A review and reconceptualization . Am J Psychiatry. 148:1991;1474-1486.
18. DeStefano N., Matthews P., Antel J.P., Preul M., Francis G., Arnold D.L. Chemical pathology of acute demyelinating lesions and its correlations with disability. Ann Neurol. 38:1995;901-909.
19. Deicken R.F., Zhou F., Corwin S., Vinogradov S., Weiner M.W. Decreased left frontal lobe N-Acetylaspartate in schizophrenia. Am J Psychiatry. 154:1997;688-690.
20. Deutch A.Y. The regulation of subcortical dopamine systems by the prefrontal cortex Interactions of central dopamine systems and the pathogenesis of schizophrenia . J Neural Transm Suppl. 36:1992;61-89.
21. Deutch A.Y., Roth R.H. The determinants of stress-induced activation of the prefrontal cortical dopamine system. Prog Brain Res. 85:1990;367-403.
22. Duyn J.H., Gillen J., Sobering G., van Zijl P.C., Moonen C.T.W. Multisection proton MR spectroscopic imaging of the brain. Radiology. 188:1993;277-282.
23. Farde L., Wiesel F., Stone-Elander S., et al. Arch Gen Psychiatry. 47:1990;213-219.
24. Frith C.D., Friston K.J., Herold S., et al. Regional brqain activity in chronic schizophrenic patients during performance of a verbal fluency task. Br J Psychiatry. 167:1995;343-349.
25. Goldberg T.E., Gold J.M. Neurocognitive deficits in schizophrenia. Hirsch S.R., Weinberger D.R. Schizophrenia. 1995;146-162 Blackwell Science Ltd, Oxford.
26. Grace A.A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity A hypothesis for the etiology of schizophrenia . Neuroscience. 41:1991;1-24.
27. Hess E.J., Bracha H.S., Kleinman J.E., Creese I. Dopamine receptor subtype imbalance in schizophrenia. Life Sci. 40:1987;1487-1497.
28. 2 receptor binding characteristics in neuroleptic naive schizophrenics studied with positron emission tomography. Arch Gen Psychiatry. 51:1994;116-123.
29. Hugg JW, Kuzniecky RI, Gilliam FG, Morawetz, R.B., R.E., F., and Hetherington, HP (1996): Normalization of contralateral metabolic function following temporal lobectomy demonstrated by 1H magnetic resonance spectroscopic imaging. Ann Neurol 40:236-239.
30. Iversen S.D. The effect of surgical lesions to frontal cortex and substantia nigra on amphetamine responses in rats. Brain Res. 31:1971;295-311.
31. Jaskiw G.E., Karoum F.K., Weinberger D.R. Persistent elevations in dopamine and its metabolites in the nucleus accumbens after mild subchronic stress in rats with ibotenic acid lesions of the medial prefrontal cortex. Brain Res. 534:1990;321-323.
32. Jaskiw G.E., Weinberger D.R. Dopamine and schizophrenia A cortically corrective perspective . Semin Neurosci. 41:1992;179-188.
33. Karreman M., Moghaddam B. The prefrontal cortex regulates the basal release of dopamine in the limbic striatum An effect mediated by ventral tegmental area . J Neurochem. 66:1996;589-598.
34. Knable M.K., Coppola R., Jones D.W., et al. Lateralized differences in iodine-123-IBZM uptake in the basal ganglia of patients with asymmetric Parkinson's disease. J Nuc Med. 36:1995;1216-1225.
35. 2 receptors, and dopamine uptake sites in post mortem striatal specimens from schizophrenic patients. Biol Psychiatry. 36:1994;827-835.
36. Kolachana B.S., Saunders R.C., Weinberger D.R. Augmentation of prefrontal cortical monoaminergic activity inhibits dopamine release in the caudate nucleus An in vivo neurochemical assessment in the rhesus monkey . Neuroscience. 69:1995;859-868.
37. 3H-spiperone binding sites in post-mortem brains from schizophrenic patients Relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms . J Neural Transm. 75:1989;1-10.
38. Kung H.F., Alavi A., Chang W., et al. In vivo SPECT imaging of CNS D-2 dopamine receptors Initial studies with iodine-123-IBZM in humans . J Nuc Med. 31:1990;573-579.
39. Laruelle M., Abi-Dargham A., van-Dyck C.H., et al. Single-photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. PNAS. 93:1996;9235-9240.
40. 2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology. 17:1997;162-274.
41. 3H-apomorphine in schizophrenic brains. Nature. 274:1978;897-900.
42. Lewis D.A. Development of prefrontal cortex during adolescence Insights into vulnerable neural circuits in schizophrenia . Neuropsychopharmacology. 16:1997;385-398.
43. Lieberman J., Kane J., Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmachology. 91:1987;415-433.
44. Louilot A., Le Moal M., Simon H. Opposite influences of dopaminergic pathways to the prefrontal cortex or the septum on the dopaminergic transmission in the nucleus accumbens. An in vivo voltammetric study. Neuroscience. 29:1989;45-56.
45. Maier M., Ron M.A., Barker G.J., Tofts P.S. Proton magnetic resonance spectroscopy an in vivo method of estimating hippocampal neuronal depletion in schizophrenia . Psychol Med. 25:1995;1201-1209.
46. Moffett J.R., Nambodiiri M.A.A. Differential distribution of N-acetylaspartylglutamate and N-acetylaspartate immunoreactivities in rat forebrain. J Neurocytol. 24:1995;409-433.
47. Nasrallah T.E., Skinner P., Schmalbrock P., Robitaille P.M. Proton magnetic resonance spectroscopy of the hippocampal formation in schizophrenia A pilot study . B J Psychiatry. 165:1994;481-485.
48. Okumura N., Otsuki S., Nasu H. The influence of insulin hypoglycaemic coma, repeated electroshocks, and chlorpromazine or beta-phenylisopropylmethylamine administration on the free amino acids in the brain. J Biochem. 46:1959;247-252.
49. Peroutka S.J., Snyder S.H. Relationship between neuroleptic effects at brain dopamine, serotonin, å-adrenergic, and histamine receptors to clinical potency. Am J Psychiatry. 137:1980;1518-1522.
50. Perrone-Bizzozzero N.I., Sower A.C., Bird E.D., Benowitz L.I., Ivins K.J., Neve R.L. Levels of the growth-associated protein GAP-43 are selectively increased in association cortices in schizophrenia. PNAS. 93:1996;14182-14187.
51. Rajkowska G., Selemon L.D., Goldman-Rakic P.S. Neuronal and glial somal size in the prefrontal cortex. Arch Gen Psychiatry. 55:1998;215-224.
52. Rango M., Spagnoli D., Tomei G., Bamonti F., Scarlato G., Zetta L. Central nervous system transsynaptic effects of acute axonal injury A 1H magnetic resonance spectroscopy study . Magn Reson Med. 33:1995;595-600.
53. Renshaw P.F., Yurgelun-Todd D.A., Tohen G.S., Cohen B.M. Temporal lobe proton magnetic resonance spectroscopy of patients with first-episode psychosis. Am J Psychiatry. 152:1995;444-446.
54. Roberts A.C., DeSalvia M.A., Wilkinson L.S., et al. 6-Hydroxydopamine lesions of the prefrontal cortex in monkeys enhance performance on an analog of the Wisconsin Card Sort Test Possible interactions with subcortical dopamine . J Neurosci. 14:1994;2531-2544.
55. Rubin Y., LaPlaca M.C., Smith D.H., Thibault L.E., Lenkinski R.E. The effect of N-acetyl-aspartate on the intracellular calcium concentration in NTera2-neurons. Neurosci Let. 198:1995;209-212.
56. Saunders R.C., Kolachana B., Bachevalier J., Weinberger D.R. Neonatal lesions of the medial temporal lobe disrupt prefrontal cortical regulation of striatal dopamine. Nature. 393:1998;169-171.
57. Schultz W., Dayan P., Montague P.R. A neural substrate for prediction and reward. Science. 275:1997;1593-1599.
58. 2 in schizophrenia: Role of endogenous dopamine and cerebellum. Commentary on The current status of PET scanning with respect to schizophrenia. Neuropsychopharmacology. 7:1992;55-57.
59. Selemon L.D., Rajkowska G., Goldman-Rakic P.S. Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. Arch Gen Psychiatry. 52:1995;805-818.
60. Taber M.T., Das S., Fibiger H.C. Cortical regulation of subcortical dopamine release Mediation via the ventral tegmental area . J Neurochem. 65:1995;1407-1410.
61. Taber M.T., Fibiger H.C. Electrical stimulation of the prefrontal cortex increases dopamine release in the nucleus accumbens of the rat Modulation by metabotropic glutamate receptors . J Neurosci. 5:1995;3896-3904.
62. Thierry A.M., Tassin J.P., Blanc G., Glowinski J. Selective activation of the mesocortical dopamine system by stress. Nature. 263:1976;242-243.
63. Vion-Dury J., Salvan A.M., Confort-Gouny S., Dhiver C., Cozzone P. Reversal of brain metabolic alterations with zidovudine detected by proton localised magnetic resonance spectroscopy. Lancet. 345:1995;60-61.
64. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry. 44:1987;660-669.
65. Weinberger D.R., Berman R.F., Zec R.F. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia I. Regional cerebral blood flow (rCBF) evidence . Arch Gen Psychiatry. 43:1986;114-125.
66. Weinberger D.R., Lipska B.K. Cortical maldevelopment, antipsychotic drugs, and schizophrenia A search for common ground . Schizophr Res. 16:1995;87-110.
67. Weinberger D.R., Berman K.F., Suddath R., Torrey E.F. Evidence of dysfunction of a prefrontal-limbic network in schizophrenia A magnetic resonance imaging and regional cerebral blood flow study of dyscordant monozygotic twins . Am J Psychiatry. 149:1992;890-897.